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Pilocytic astrocytomas (PAs) are the most common brain
tumors of childhood1 and can arise anywhere within the
neuroaxis, including the posterior fossa (pf-PA), supratentorial
midline (sm-PA; including optic pathway, hypothalamus,
thalamus), supratentorial cortex (sc-PA), brainstem (bs-PA),
and spinal cord (sp-PA). While tumor location (sm, bs) has
been proposed as a prognostic factor associated with poor
progression-free survival (PFS),2–4 this effect is abrogated
when resection status (gross total resection [GTR], subtotal
resection [STR]) is included.2,4 To determine whether tumor
location has any value in predicting PA clinical outcome, we
evaluated clinical outcomes of children with biopsy-proven
PA treated at St. Louis Children’s Hospital between 2003
and 2021 (n = 251). Subjects with a diagnosis of neurofibromatosis type 1 (NF1; n = 13) and those with discrepancies in
their pathologic diagnosis (n = 11) or missing pertinent clinical data (n = 36) were excluded, leaving 191 total subjects for
analysis. Consistent with prior reports,5 children with sc-PA
were typically older at diagnosis than those with pf-PA. There
were no differences in PA location incidence by sex,1 but individuals with sm-PA and bs-PA had higher rates of STR (Figure
1A) and reduced PFS (Figure 1B).2,3 Importantly, this difference
in PFS was related to resection status, such that longer PFS
was observed in sm-JPA and bs-JPA cases in which a GTR was
achieved (Figure 1C).
To remove resection status as a confounding variable, we
subsequently analyzed the outcomes of children with STR PAs
(n = 81) by brain location. While the overall percentage of cases
that demonstrated radiographic evidence of progression was
not different between groups, we found that more children
with sm-PA had two or more progression events (Figure 1D),
and 75% of subjects with three or more progression events
harbored sm-PAs (not shown). Furthermore, the only children

in our cohort with leptomeningeal dissemination or death harbored sm-PAs (Figure 1D). Consistent with these observations,
no differences in PFS by location were observed between
subjects with STR PAs at initial progression (Figure 1E); however, those with sm-PAs exhibited shorter times to second progression (Figure 1F).
To determine how differences in clinical course by brain
location affected neurologic outcomes, we then quantified
neurologic deficits at diagnosis, relapse, and last follow-up
in subjects with STR PA. One point was awarded for the presence of each deficit at initial diagnosis, including unilateral
facial weakness, dysphagia, dysarthria, unilateral upper extremity weakness, unilateral lower extremity weakness, vision loss, hearing loss, each endocrinopathy present, ataxia,
mutism, seizures, and severe cognitive impairment. At follow-up, one point was added for worsening symptoms or
new symptoms and removed for resolved symptoms. A halfpoint was removed for improving, but not resolved, neurologic signs/symptoms. Scores at follow-up were subtracted
from scores at initial diagnosis to generate a curve over
time, with each subject’s score at diagnosis acting as an internal standard. As expected, there were qualitative differences in neurologic deficits by brain location, with vision loss
and endocrinopathies more prevalent in sm-PA, and weakness and bulbar symptoms more prevalent in bs-PA. While
the number of neurologic deficits did not differ by brain location at initial diagnosis (Figure 1G), children with sm-PA
exhibited more neurologic deficits over time (Figure 1H), frequently due to worsening vision and the acquisition of new
endocrinopathies or weakness. In contrast, subjects with
bs-PA typically displayed deficits at initial presentation or in
the immediate postoperative period that remained stable or
improved over time.
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Figure 1. Children with supratentorial midline pilocytic astrocytomas (PAs) exhibit greater rates of progression and acquisition of neurologic
deficits over time. (A) One hundred ninety-one evaluable subjects with biopsy-proven PA were treated at St. Louis Children’s Hospital between 2003
and 2021. While no differences in male/female incidence by brain location were observed, differences in the age at initial presentation were noted
between subjects with pf-PA vs sc-PA (1-way ANOVA with correction for multiple comparisons using a Tukey post hoc test, P < 0.05). Gross total
resection (GTR) was also different by location, with sm-PA and bs-PA having a higher percentage of subtotal resection (STR) tumors (P < 0.0001;
Fisher’s exact test). (B) Progression-free survival (PFS) differed by PA location, with subjects harboring sm-PA and bs-PA tumors demonstrating
shorter PFS (Mantel-Cox log-rank test; P < 0.0001). (C) Longer PFS was observed in sm-PA and bs-PA subjects with a GTR relative to those with a
STR (P < 0.0001; Mantel-Cox log-rank test). (D) Subjects with sm-PAs displayed higher rates of multiple progression events (P < 0.05; Fisher’s exact
test). All cases of leptomeningeal dissemination and death occurred in subjects with sm-PA. (E) There was no difference in PFS from diagnosis
to first relapse by location. (F) Subjects with sm-PA exhibited shorter PFS from the completion of initial therapy to the second relapse (P < 0.01;
Mantel-Cox log-rank test). (G) There were no significant differences in the number of neurologic deficits by brain location at diagnosis. (H) The
change in number and severity of neurologic deficits was quantitated in subjects with sm-PA and bs-PA at first relapse, second relapse, and last
follow-up date compared to initial diagnosis. Subjects with sm-PA had a greater accumulation of neurologic deficits over time than those with
bs-PA (P < 0.01, mixed-effects analysis). (I) In subjects for whom tumor molecular testing data were available, those with sm-PA showed a significantly lower percentage of BRAF fusions (P < 0.001) and a higher percentage of both non-BRAF mutations (P < 0.05) and multiple mutations
(P < 0.005) relative to pf-PA.
  

Given that different driver mutations may also affect clinical prognosis in pediatric low-grade glioma
(pLGG),5 we next determined whether mutations differed
by brain location. Molecular testing data were available
for 51 subjects (22 GTR, 29 STR), which included BRAFfusion analysis by FISH (n = 51), BRAFV600E detection
by immunohistochemistry (n = 50), and targeted tumor
sequencing (n = 25; 14 pf-PA, 8 sm-PA, 3 bs-PA). Similar
to prior reports, we found that subjects with sm-PA had
more non-BRAF-fusion alterations identified (Figure
1I),5,6 including oncogenic mutations in BRAF (V600E,
D594G), FGFR1, PTPN11, and other (KMT2C, CDH1) genes.
Additionally, sm-PAs had a greater occurrence of multiple
oncogenic mutations compared to pf-PAs (25% vs 10%
of cases; Figure 1I), with secondary mutations in either

PTPN11 or CDH1 identified in 75% of sm-JPAs with multiple mutations.
Taken together, we identified a subgroup of children with
PA with a more aggressive clinical course, greater numbers of neurological deficits acquired over time, and an elevated prevalence of non-BRAF-fusion genetic alterations.
By restricting our analysis to STR PA cases, we eliminated
resection status as a confounding variable, and confirmed
location as an independent prognostic factor. Similar to
prior studies,2,4 the effect of location was eliminated for PA
in which GTR could be achieved.
In our series, children with m-PA also displayed
worsening neurological deficits over time, a finding not
reported in prior studies.7 This discrepancy may be due to
methodology, as our study included only subjects with PA,
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excluded those with GTR, and removed individuals with
NF1, who often develop sm-LGG with a more indolent
course.8,9 The clinical course of sporadic sm-PA was more
reminiscent of deep extensive tumors in children with NF1,
which arise in younger subjects, require multiple treatments, and exhibit a shorter mean PFS.10
The higher rates of multiple progression, which correlates with increased neurologic morbidity, in young
children with sporadic STR sm-PA suggests that treating
neuro-oncologists may consider early intervention at first
progression, rather than watch-and-wait strategies. These
at-risk children may also benefit from earlier consideration
of molecularly targeted therapy.
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